NCT05243732

Music Listening for Wellbeing in Adults With Acquired Visual Impairment

Completed NA Last updated 6 December 2022

What this trial tests

NA trial testing Mindful Music Listening in Visual Impairment in 81 participants. Completed in 1 December 2022.

Timeline

15 January 2022

Primary endpoint
30 August 2022

1 December 2022

Quick facts

Lead sponsor	Anglia Ruskin University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	81
Start date	15 January 2022
Primary completion	30 August 2022
Estimated completion	1 December 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

• Mindful Music Listening
• Music Listening

Conditions studied

• Visual Impairment — all drugs for Visual Impairment →
• Low Vision — all drugs for Low Vision →
• Depression — all drugs for Depression →
• Anxiety — all drugs for Anxiety →

Sponsor

Anglia Ruskin University

Who can join

18 and older, any sex, with Visual Impairment or Low Vision. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A visual impairment (VI) is often associated with reduced psychological wellbeing. Music can be used in a variety of ways to promote psychological wellbeing. Music intervention studies demonstrate that listening to music can provide a distraction from unpleasant thoughts/feelings. Hence, music may serve as a catalyst to improve mood and relieve feelings of depression, anxiety, and stress.

The purpose of this study is to investigate if it is feasible for people with acquired VI to self-deliver daily music listening (music alone or with mindful music listening instructions) for wellbeing, in participants homes, for four-weeks, and to collect data remotely on efficacy in reducing symptoms of anxiety and depression and treatment fidelity.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Music listening for psychological well-being in adults with acquired vision impairment: a feasibility randomised controlled trial.
   Somani N, Street A, Beukes EW, Zhang J, et al · · 2025 · PMID 40071281 · DOI 10.3389/fpsyt.2025.1505283